The 12 closest competitors and alternatives to CellCure among biotechnology companies — ranked by similarity to what CellCure actually does, not by market-cap band.
Subscribe to see CellCure’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CellCure Neurosciences is an Israeli biotechnology company developing cell-based therapies derived from pluripotent stem cells, notably retinal pigment epithelium cells for treating retinal diseases such as geographic atrophy associated with dry age-related macular degeneration. Its intended customers and beneficiaries include ophthalmology researchers, clinical partners, and patients with degenerative retinal conditions.
CellCure is a biotechnology company headquartered in Israel. Its most recent funding round, Seed, raised $3M in March 2006.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to CellCure by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Neurotech Pharmaceuticals is a biotechnology company that develops transformative therapies for chronic eye diseases, utilizing its proprietary Encapsulated Cell Therapy platform. The company serves patients with conditions such as Macular Telangiectasia Type 2 by providing advanced treatments designed to protect against progressive vision loss.
Biotech
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Biotech
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Similar biotechnology company
Acucela is a biotechnology company developing ophthalmic therapeutics for retinal diseases, including age-related macular degeneration and Stargardt disease. Its research has included visual-cycle modulators such as emixustat, aimed at treating degenerative eye conditions.
Biotech
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Similar biotechnology company
Aurion Biotech Inc. develops regenerative cell therapies for ophthalmology, focusing on treatments for corneal endothelial disease and vision loss. Its lead product, AURN001, is a combination therapy utilizing human corneal endothelial cells designed to restore corneal clarity and provide a minimally invasive alternative to traditional donor tissue transplantation. The company serves patients suffering from blindness and provides advanced treatment options for ophthalmologists.
Biotech
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Similar biotechnology company
OphRx is an Israeli biotechnology company founded in 2014 that specializes in developing noninvasive, topical drug delivery solutions for eye diseases utilizing lyotropic liquid crystals. The company is in the preclinical stage of developing novel treatments, including product candidates for front- and back-of-the-eye conditions.
Similar biotechnology company
OcuCure Therapeutics, Inc. is an ophthalmic pharmaceutical company located in Virginia that focuses on developing new proprietary drugs at the intersection of medical research and healthcare solutions.
Similar biotechnology company
Broadwing Bio is a biotechnology company that develops antibody-based therapies to treat major causes of adult vision loss, specifically focusing on Geographic Atrophy and Glaucoma. The company utilizes genetics-driven insights to target ocular diseases and preserve vision for patients.
Similar biotechnology company
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Similar biotechnology company
Memento Medicines, Inc. is a privately held biotechnology company headquartered in Boston, Massachusetts, focused on developing novel biologic therapies for retinal diseases.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for CellCureand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →